Unassociated Document
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
     CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
April 20, 2009
 
(Date of Earliest Event Reported)
 
Advaxis, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
00028489
02-0563870
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)

 
Technology Centre of New Jersey
675 Rt. 1, Suite B113
North Brunswick, N.J. 08902
(Address of principal executive offices)
 
(732) 545-1590 (Registrant’s telephone number, including area code)
 
 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Item 8.01      Other Events
 
          On April 20, 2009, Advaxis, Inc. issued a press release regarding its drug licensing discussions for its flagship vaccine construct, ADXS11-001 and the postponement of its annual shareholders’ meeting until further notice.
 
          A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.
 
Item 9.01      Financial Statements and Exhibits
 
99.1                     Advaxis, Inc. press release, dated April 20, 2009
 
 
SIGNATURE
 
 
         Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: April 20, 2009
 
 
Advaxis, Inc.
 
 
 
By:
/s/ Thomas A. Moore
 
Name:
Thomas A. Moore
 
Title:
Chief Executive Officer